Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia begins Phase II hypertension study
The objective of the randomized, double-blind, placebo-controlled, parallel-group study is to evaluate PS433540 safety and efficacy in subjects with Stage I and Stage II hypertension. PS433540 is a
The objective of the randomized, double-blind, placebo-controlled, parallel-group study is to evaluate PS433540 safety and efficacy in subjects with Stage I and Stage II hypertension. PS433540 is a
<p>The Times quoted David Smith, AstraZeneca's executive vice-president of operations, as saying that the company aimed to become a pure research, development and marketing organization. <br /><br />According
Additionally, upon clearance of this IND Hollis-Eden may also consider commencing exploratory studies in the fourth quarter of 2007 to evaluate HE3286 in one or more acute inflammatory
Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor. The vicriviroc
The most common methods of hernia mesh fixation include sutures and tacking systems. Between 10 and 20% of patients complain of pain resulting from hernia repair, most often
LGD-3303 is a selective androgen receptor full agonist in skeletal muscle, a target tissue for androgen action. By comparison, in the prostate and sebaceous glands, the compound is
IMO-2125 is a novel agonist of toll-like receptor 9. The trial is designed to assess the safety and tolerability of IMO-2125 at different dose levels as well as
Under the terms of the agreement, Forest will initially pay Microbia $70 million in licensing fees. Microbia and Forest will jointly and equally fund development and commercialization of
Glucagon is a hormone produced by the pancreas that stimulates the liver to produce glucose (sugar). Overproduction of glucose by the liver is an important cause of high
Gwen Krivi, vice president of Lilly research laboratories, said: “The FDA’s decision marks a major milestone. For the first time, postmenopausal women with osteoporosis will have one treatment